VPS18 and type 1 diabetes mellitus: Furthermore, consistent with immune dysregulation in type 1 diabetes, CD4+ Teff activated PD1high were decreased in type 1 diabetes patients at day 6 of anti-CD3/CD28 stimulation upon Pep3 pretreatment.